Compare Crispr Therapeutics AG (CRSP) vs Global X Autonomous & Electric Vehicles (DRIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Global X Autonomous & Electric Vehicles — how do they compare? Crispr Therapeutics AG trades at $54.02 (market cap $5.23B), while Global X Autonomous & Electric Vehicles trades at $35.8. The key difference: Global X Autonomous & Electric Vehicles is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | DRIV | |
|---|---|---|
Market Cap | $5.23B | — |
Sector | Health | Sector/Thematic |
52-Week High | $76.78 | $42.53 |
52-Week Low | $44.34 | $25.23 |
Enterprise Value | $3.65B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
DRIV trades at $35.92, up 0.98% on the day, with a bullish technical signal supported by moving averages and ADX indicators. The stock shows strong momentum, though the short-term RSI suggests overbought conditions. Recent news highlights global EV sales growth and China's aggressive expansion, benefiting the sector. A dividend of $0.07 is scheduled for July 2026, adding income potential.
Outlook remains positive due to sector tailwinds from rising EV adoption and fuel price pressures. Key risks include competitive threats from Chinese automakers and regulatory delays. Analysts are generally bullish, but investors should monitor valuation gaps and execution risks amid rapid industry shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Global X Autonomous & Electric Vehicles
DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.
Read more on DRIV →
